New vaccine aims to stop colorectal and pancreatic cancer from coming back
NCT ID NCT07353645
First seen Jan 23, 2026 · Last updated May 01, 2026 · Updated 15 times
Summary
This study tests a new vaccine made from engineered bacteria that targets KRAS mutations in colorectal and pancreatic cancer patients who have had surgery and chemotherapy but are at high risk of their cancer returning. The vaccine is designed to train the immune system to attack cancer cells. The trial will check if the vaccine is safe and helps prevent cancer recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University
RECRUITINGNanjing, Jiangsu, 210008, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.